英文名稱(chēng) | Tesirine | SG3249 |
---|---|
中文名稱(chēng) | 特司林 |
CAS號(hào) | 1595275-62-9 |
分子式 | C75H101N9O23 |
分子量 | 1496.65 |
外觀 | White to light yellow powder |
儲(chǔ)存條件 | Avoid light, nitrogen, -20 ℃ |
規(guī)格 | 庫(kù)存 | 目錄價(jià) | 會(huì)員專(zhuān)享價(jià) | 數(shù)量 |
---|---|---|---|---|
1 mg | 3-5days | ¥21660.00 | 登錄后可見(jiàn) | |
5 mg | 3-5days | ¥46360.00 | 登錄后可見(jiàn) |
英文名稱(chēng) | Tesirine | SG3249 |
---|---|
中文名稱(chēng) | 特司林 |
CAS號(hào) | 1595275-62-9 |
分子式 | C75H101N9O23 |
分子量 | 1496.65 |
外觀 | White to light yellow powder |
儲(chǔ)存條件 | Avoid light, nitrogen, -20 ℃ |
Tesirine (SG-3249; SG3249), cathepsin B-cleavable valine-alanine pyrrolobenzodiazepine (PBD) dimer used as an antibody-drug conjugate (ADC) payload; Tesirine was designed to combine the potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. Rovalpituzumab tesirine is a first-in-class ADC directed against delta-like protein 3 (DLL3), a novel target identified in tumour-initiating cells and expressed in small-cell lung cancer.
PMID: 29992976 PMCID: PMC6041317 DOI: 10.1038/s41598-018-28533-4